Advertisement

Topics

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA (Denosumab) To Include Multiple Myeloma Patients

20:00 EDT 18 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA (Denosumab) To Include Multiple Myeloma Patients

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA (Denosumab) To Include Multiple Myeloma Patients"

Advertisement
Quick Search
Advertisement
Advertisement